A Study of Safety and Pharmacokinetics of Repeated Dose of Micafungin as Antifungal Prophylaxis in Children and Adolescents Who Undergo Hematopoietic Stem Cell Transplant

Astellas

Status and phase

Completed

Phase 1

Conditions

Fungal Infections

Treatments

Drug: Micafungin

Study type

Interventional

Funder types

Industry

Identifiers

NCT00606268

9463-CL-2103

Details and patient eligibility

About

The study will evaluate PK and safety of two dose levels of Micafungin (FK463) as Antifungal prophylaxis in children and adolescents undergoing HSCT

Full description

This is a prospective, multi-center, open-label, repeat-dose pharmacokinetic study that contains two treatment (micafungin 1.0mg/kg and 1.5mg/kg) dose groups. Subjects will be enrolled according to age and stratified by weight to receive either 1.0mg/kg (weight > 25kg) or 1.5mg/kg ( weight < 25kg) micafungin.

Children (4 months to < 2years, 2 to 5 years and 6 to 11 years) and adolescents (12 to 16 years) undergoing HSCT who require antifungal prophylaxis will be enrolled

Enrollment

42 patients

Sex

All

Ages

4 months to 16 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Institutional Review Board (IRB)-approved written informed Consent / Assent (as applicable) and HIPAA Authorization must be obtained from the subject (as able) and /or subject's parent/legally authorized representative prior to any study-related procedures
Subject has sufficient venous access to permit administration of study drug, collect pharmacokinetic samples and monitor laboratory safety variables
Female subject of childbearing potential must have a negative pregnancy test within 72 hours prior to the first dose of study drug, and if sexually active agree method of birth control per Investigator judgment for the duration of the study
Subject (when able) and /or subjects parent/legally authorized representative agree to comply with the study requirements and with the concomitant medication restrictions
Subject plans to undergo a HSCT

Exclusion criteria

Subject has evidence of significant liver disease as defined by aspartate transamine (AST/SGOT), alanine transaminases (ALT/SGPT) 10 times the upper limit of normal (ULN) and total bilirubin or alkaline phosphatase > 5 times the ULN
Subject has concomitant medical condition that in the opinion of the Investigator and /or medical monitor precludes enrollment into the study
Subject with evidence of an active systemic or disseminated fungal infection prior to enrollment
Subject has a history of anaphylaxis, hypersensitivity, or any serious reactions to the echinocandin class of antifungals
Subject had received treatment with an echinocandin within one week prior to first dose of study drug
Subject status is unstable and subject is unlikely to complete required study procedures
Female subject is pregnant or nursing. Females of childbearing potential must avoid becoming pregnant while receiving study drug